BioSpace News Archive

Mirum Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for LIVMARLI® oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome two months of age and older.

Sphere Fluidics announced that it has appointed Richard Hammond as Chief Technical Officer.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Health Canada has approved the company’s fourth-generation rechargeable sacral neuromodulation system.

European Commission approves SPEVIGO ® (spesolimab) for generalized pustular psoriasis flares.

AEON Biopharma, Inc. and Priveterra Acquisition Corp. announced that they have entered into a definitive business combination agreement.

ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”) today announced the United States Food and Drug Administration’s (“FDA”) approval for its supplemental Biologics License Applications (BLAs) for both ASCENIV and BIVIGAM to now include room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life.

Flagship Pioneering, the bioplatform innovation company, unveiled Montai Health, a company unlocking the power of nature with its CONECTA™ platform to create medicines that treat and preempt a broad range of chronic diseases.

Terray Therapeutics today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as Strategic Advisor to the Board of Directors and Leadership Team.

Empyrean Neuroscience, Inc. today announced its scientific advisory board.

ESSA Pharma Inc. today provided a corporate update and reported financial results for the fiscal year ended September 30, 2022.